Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/II clinical trial for adenosine, an immune checkpoint. Its preclinical stage products include CPI-182, an antibody to block neutrophil function and migration, and myeloid derived suppressor cells; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
IPO Year: 2016
Exchange: NASDAQ
Website: corvuspharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/2/2025 | $11.00 | Buy | H.C. Wainwright |
8/18/2023 | $7.00 | Outperform | Oppenheimer |
12/3/2021 | $5.00 → $8.00 | Overweight | Cantor Fitzgerald |
12/1/2021 | $8.00 | Buy | Jefferies |
8/3/2021 | $4.00 → $3.50 | Neutral | Mizuho |
7/16/2021 | $9.50 → $6.00 | Buy | HC Wainwright & Co. |
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
3 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
H.C. Wainwright initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $11.00
Oppenheimer initiated coverage of Corvus Pharmaceuticals with a rating of Outperform and set a new price target of $7.00
Cantor Fitzgerald reiterated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $5.00 previously
Jefferies resumed coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $8.00
Mizuho reiterated coverage of Corvus Pharmaceuticals with a rating of Neutral and set a new price target of $3.50 from $4.00 previously
HC Wainwright & Co. reiterated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $9.50 previously
Cantor Fitzgerald initiated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $10.00
HC Wainwright & Co. reiterated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $9.50 from $12.00 previously
Mizuho downgraded Corvus Pharmaceuticals from Buy to Neutral and set a new price target of $4.00 from $7.00 previously
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)
4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)